For instance, the 2019 European Society of Cardiology (ESC) guidelines for the management of T2DM, pre-diabetes, and CVD developed in collaboration with the EASD recognize the role of GLP1-RAs in reducing the risk of MACE in patients with T2DM and CVD [122]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.